In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase

Chemical Biology and Drug Design

Volumn 85, Issue 4, 2015, Pages 427-438

  Li, Chao ^a   Fang, Jian Song ^a   Lian, Wen Wen ^a   Pang, Xiao Cong ^a   Liu, Ai Lin ^a,b,c   Du, Guan Hua ^a,b,c  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Beijing Key Laboratory of Drug Target Research and Drug Screening   (China)

^c State Key Laboratory of Bioactive Substance and Function of Natural Medicines   (China)

Author keywords

CoMFA; CoMSIA; CPE; docking; NA; RV (3 5 4 trihydroxy trans stilbene) derivatives

Indexed keywords

ANTIVIRUS AGENT; RESVERATROL; RIBAVIRIN; SIALIDASE; STILBENE DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; IC50; IN VITRO STUDY; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS; VIRUS PARTICLE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DOG; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG DESIGN; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR DOCKING SIMULATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STILBENES;

EID: 84924419664     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12425     Document Type: Article

References (52)

1. Scalera N.M., Mossad S.B., (2009) The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad Med; 121: 43-47.
2. Myers K.P., Olsen C.W., Gray G.C., (2007) Cases of swine influenza in humans: a review of the literature. Clin Infect Dis; 44: 1084-1088.
3. Padgett B.L., Walker D.L., (1964) Enzymatic variants of influenza virus. III. Function of neuraminidase in the viral growth cycle. J Bacteriol; 87: 363-369.
4. Ohuchi M., Asaoka N., Sakai T., Ohuchi R., (2006) Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect; 8: 1287-1293.
5. Su B., Wurtzer S., Rameix-Welti M.A., Dwyer D., van der Werf S., Naffakh N., et al,. (2009) Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS ONE; 4: e8495.
6. Colman P.M., Varghese J.N., Laver W.G., (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature; 303: 41-44.
7. Klenk H.D., Rott R., (1988) The molecular biology of influenza virus pathogenicity. Adv Virus Res; 34: 247-281.
8. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.-D., (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol; 78: 12665-12667.
9. Stiver G., (2003) The treatment of influenza with antiviral drugs. Can Med Assoc J; 168: 49-57.
10. Cho H.G., Choi J.H., Lee H.K., Mun S.K., Lee J.B., Jho E.H., et al,. (2013) Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010. Arch Virol; 158: 2365-2370.
11. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G., (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol; 83: 10366-10373.
12. Heider H., Adamczyk B., Presber H.W., Schroeder C., Feldblum R., Indulen M.K., (1981) Occurrence of amantadine- and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Virol; 25: 395-400.
13. Moscona A., (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med; 360: 953-956.
14. Saiko P., Szakmary A., Jaeger W., Szekeres T., (2008) Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res; 658: 68-94.
15. Pallas M., Porquet D., Vicente A., Sanfeliu C., (2013) Resveratrol: new avenues for a natural compound in neuroprotection. Curr Pharm Des; 19: 6726-6731.
16. Osman A.M., Al-Harthi S.E., Alarabi O.M., Elshal M.F., Ramadan W.S., Alaama M.N., et al,. (2013) Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int; 13: 52.
17. Babizhayev M.A., Deyev A.I., Yegorov Y.E., (2013) Non-hydrolyzed in digestive tract and blood natural L-carnosine peptide ('bioactivated Jewish penicillin') as a panacea of tomorrow for various flu ailments: signaling activity attenuating nitric oxide (NO) production, cytostasis, and NO-dependent inhibition of influenza virus replication in macrophages in the human body infected with the virulent swine influenza A (H1N1) virus. J Basic Clin Physiol Pharmacol; 24: 1-26.
18. Yin H.T., Tian Q.Z., Guan L., Zhou Y., Huang X.E., Zhang H., (2013) In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev; 14: 1703-1706.
19. Fremont L., (2000) Biological effects of resveratrol. Life Sci; 66: 663-673.
20. Palamara A.T., Nencioni L., Aquilano K., De Chiara G., Hernandez L., Cozzolino F., et al,. (2005) Inhibition of influenza A virus replication by resveratrol. J Infect Dis; 191: 1719-1729.
21. Liu A.L., Yang F., Zhu M., Zhou D., Lin M., Lee S.M., et al,. (2010) In vitro anti-influenza viral activities of stilbenoids from the lianas of Gnetum pendulum. Planta Med; 76: 1874-1876.
22. Piao Z.S., Feng Y.B., Wang L., Zhang X.Q., Lin M., (2010) Synthesis and HIV-1 inhibitory activity of natural products isolated from Gnetum parvifolium and their analogues. Acta Pharm Sin B; 45: 1509-1515.
23. Feng Y.B., Wang L., Zhao Z.Z., (1998) Synthesis of the natural products Resveratrol (I) and IsorhaPotogenin (II). Chin Chem Lett; 9: 1003-1004.
24. Piao Z.S., Wang L., Zhao Z.Z., (2000) Total synthesis of the natural product-pinosylvin and its analog. Chin Chem Lett; 11: 677-678.
25. Piao Z.S., Wang L., Feng Y.B., Zhao Z.Z., (2002) Studies on a natural product-piceatannol and its analog. Chin Chem Lett; 13: 521-524.
26. Li J.B., Lin M., Li S.Z., Song W.Z., (1991) Studies on the structure of Gnetifolin A of Gnetum parvifolium (Warb.) C.Y. Cheng. Acta Pharm Sin B; 26: 437-441.
27. Nilakantan R., Bauman N., Venkataraghavan R., (1993) New method for rapid characterization of molecular shapes: applications in drug design. J Chem Inf Comput Sci; 33: 79-85.
28. Engel J., Schumacher W., Schonenberger H., (1986) Design of metallocenic drugs. IARC Sci Publ; 78: 295-307.
29. Kujumgiev A., Tsvetkova I., Serkedjieva Y., Bankova V., Christov R., Popov S., (1999) Antibacterial, antifungal and antiviral activity of propolis of different geographic origin. J Ethnopharmacol; 64: 235-240.
30. Zu M., Yang F., Zhou W., Liu A., Du G., Zheng L., (2012) In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. Antiviral Res; 94: 217-224.
31. Potier M., Mameli L., Belisle M., Dallaire L., Melancon S.B., (1979) Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem; 94: 287-296.
32. Liu Y., Zhang L., Gong J., Fang H., Liu A., Du G., et al,. (2011) Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors. J Enzyme Inhib Med Chem; 26: 506-513.
33. Zhang J., Wang Q., Fang H., Xu W., Liu A., Du G., (2008) Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors. Bioorg Med Chem; 16: 3839-3847.
34. Zhang J., Xu W., Liu A., Du G., (2008) Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors. Med Chem; 4: 206-209.
35. Cramer R.D., Patterson D.E., Bunce J.D., (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc; 110: 5959-5967.
36. Cramer R.D., Bunce J.D., Patterson D.E., Frank I.E., (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat; 7: 18-25.
37. Klebe G., Abraham U., Mietzner T., (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem; 37: 4130-4146.
38. Ruan Z.X., Huangfu D.S., Xu X.J., Sun P.H., Chen W.M., (2013) 3D-QSAR and molecular docking for the discovery of ketolide derivatives. Exp Opin Drug Discov; 8: 427-444.
39. Cho S.J., Tropsha A., (1995) Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J Med Chem; 38: 1060-1066.
40. Gasteiger J., Marsili M., (1978) A new model for calculating atomic charges in molecules. Tetrahedron Lett; 19: 3181-3184.
41. Golbraikh A., Tropsha A., (2002) Beware of q2! J Mol Graph Model; 20: 269-276.
42. Ståhle L., Wold S., (1987) Partial least squares analysis with cross-validation for the two-class problem: a Monte Carlo study. J Chemom; 1: 185-196.
43. Wold S., (1978) Cross-validatory estimation of the number of components in factor and principal components models. Technometrics; 20: 397-405.
44. Patel P.D., Patel M.R., Kaushik-Basu N., Talele T.T., (2008) 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model; 48: 42-55.
45. Gao L., Zu M., Wu S., Liu A.L., Du G.H., (2011) 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase. Bioorg Med Chem Lett; 21: 5964-5970.
46. Fang J., Huang D., Zhao W., Ge H., Luo H.B., Xu J., (2011) A new protocol for predicting novel GSK-3beta ATP competitive inhibitors. J Chem Inf Model; 51: 1431-1438.
47. Huang H.-J., Lee K.-J., Yu H.W., Chen C.-Y., Hsu C.-H., Chen H.-Y., et al,. (2010) Structure-based and ligand-based drug design for HER 2 receptor. J Biomol Struct Dyn; 28: 23-37.
48. Taylor N.R., Cleasby A., Singh O., Skarzynski T., Wonacott A.J., Smith P.W., et al,. (1998) Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4 H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J Med Chem; 41: 798-807.
49. Gao L.L., Chen Q., Li J.D., Zhu W.C., Guo J., Yu S.Y., (2011) [Inhibitory effect of resveratrol against enterovirus type 71 in vitro]. Nan Fang Yi Ke Da Xue Xue Bao; 31: 665-668.
50. Buolamwini J.K., Assefa H., (2002) CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem; 45: 841-852.
51. Compans R.W., Dimmock N.J., Meier-Ewert H., (1969) Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol; 4: 528-534.
52. Palese P., Tobita K., Ueda M., Compans R.W., (1974) Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology; 61: 397-410.